---

title: Bell's Palsy Treatment
authors:
    - Michelle Lin, MD
created: 2013/02/21
updates:
    - 2017/02/13
categories:
    - Neurology
---

# Bell's Palsy: Treatment

\##Treatment

- Corticosteroids, if onset within 72 hours
- 1 in 11 were helped (to complete recovery) - [NNT.com](http://www.thennt.com/nnt/steroids-for-bells-palsy/)
- **<span class="drug">Prednisone</span>:** 60 daily x 1 week. May consider taper for days #8-10
- <span class="drug">Artificial tears</span> in daytime and lubricating eye ointment at night to prevent corneal drying and exposure. 
- Tape eyelid shut while asleep.

Controversial benefit of antivirals (at most risk difference of 7%):

- American Academy of Neurology (2012), JAMA (2009), and UpToDate suggest giving for severe cases such as for Grade IV and higher
- Cochrane review (2009): No antivirals indicated. 
- **<span class="drug">Valacylovir**</span> 1000 mg TID or **<span class="drug">Acyclovir**</span> 400 mg 5x daily x 1 week
- Also prescribe <span class="drug">corticosteroids</span>, if antivirals given.

## House-Brackmann grading for severity of facial nerve weakness

|  Grade |    Dysfunction    | Gross weakness                                                                                                     | At rest                  |  Motion                                                                                 |
| :----: | :---------------: | ------------------------------------------------------------------------------------------------------------------ | ------------------------ | --------------------------------------------------------------------------------------- |
|    I   |        None       | No weakness                                                                                                        | No weakness              | Normal function all groups                                                              |
|   II   |        Mild       | Slight weakness noticeable on close inspection. May have very slight synkinesis                                    | Normal symmetry and tone | **Forehead**: Moderate-to-good function  **Mouth**: Slight asymmetry                    |
|   III  |      Moderate     | Obvious but not disfiguring difference; noticeable but not severe synkinesis, contracture, and/or hemifacial spasm | Normal symmetry and tone | **Forehead**: Slight-to-moderate movement  **Mouth**: Slightly weak with maximum effort |
|   IV   | Moderately severe | Obvious weakness and/or disfiguring asymmetry                                                                      | Normal symmetry and tone | **Forehead**: None  **Mouth**: Asymmetric with maximum effort                           |
|    V   |       Severe      | Only barely perceptible motion                                                                                     | Asymmetry                | **Forehead**: None      **Mouth**: Slight movement                                      |
|   VI   |  Total paralysis  | No movement                                                                                                        | Asymmetry                | None for all groups                                                                     |

## References

- [Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012 Nov 27;79(22):2209-13. doi: 10.1212/WNL.0b013e318275978c. Epub 2012 Nov 7.](https://www.ncbi.nlm.nih.gov/pubmed/23136264)
- [de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VY, Nedzelski JM, Chen JM. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA. 2009 Sep 2;302(9):985-93. doi: 10.1001/jama.2009.1243.](https://www.ncbi.nlm.nih.gov/pubmed/?term=19724046)
- [Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2009 Oct 7;(4):CD001869. doi: 10.1002/14651858.CD001869.pub4.](https://www.ncbi.nlm.nih.gov/pubmed/19821283)
